AptarGroup, Inc (ATR) Fair Value & Analysis
Healthcare · US · Market cap $8.6B
AptarGroup, Inc
ATR · US
Fair value as of: Jul 17, 2026
From 26 valuation models · updated 23 days ago
Share price +9.0% over the past month.
A solid business, but screening 37% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($127.37). The favourable scenario is already priced in.
- Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range ($49.92 to $127.37) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.
How to read this chart
60‑month range $88.90 – $172.64 · fair‑value band $49.92 – $127.37 · the $135.42 price screens above the $84.83 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 17, 2026.
Analysis
AptarGroup, Inc (ATR) currently trades at $135.42, while our model-based Fair Value estimate is $84.83, implying the stock looks roughly 37.4% overvalued today. The Quality Score stands at 57/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, AptarGroup, Inc generated revenue of $3.9B at a net margin of 10.0%. Revenue grew 10.8% year over year. It earns a return on equity of 14.8%. Net debt stands at $1.1B. Fundamentals as of Jul 17, 2026
Our scenario range runs from $49.92 (bear case) to $127.37 (bull case); at $135.42, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 17% below its 52-week high and 32% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -37%, ATR screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Multiples ($100.84) versus Dividend Discount ($26.00). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 57 · Market factors (momentum, volatility) 58
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
AptarGroup, Inc. designs and manufactures drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, fragrance, facial skincare, color cosmetics, personal care, home care, and food and beverage markets. The company operates through three segments: Pharma, Beauty, and Closures.
Full company description
AptarGroup, Inc. designs and manufactures drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, fragrance, facial skincare, color cosmetics, personal care, home care, and food and beverage markets. The company operates through three segments: Pharma, Beauty, and Closures. It provides dispensing pumps used to dispense sprays, liquids, or lotions from non-pressurized containers; fine-mist pumps for pharmaceutical and fragrance applications; and lotion pumps for viscous formulations, as well as closures, such as dispensing and non-dispensing solutions that enable product delivery without removal of the cap and used across various consumer end markets. The company also offers aerosol valves used in pressurized containers and continuous spray and metered-dose valves for pharmaceutical, personal care, and household applications; elastomeric primary packaging components; active material science solutions; and digital health solutions. The company primarily sells its products and services in Asia, Europe, Latin America, and North America. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
AptarGroup, Inc reported revenue of $3.8B in FY2025 versus $3.2B in FY2021, a compound +4.0%/yr. Reported net income was $393M in FY2025, compounding +12.6%/yr from FY2021.
ATR screens 37% overvalued. Compare with Intuitive Surgical, Inc →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- AptarGroup Q2 Earnings Beat Estimates on Pharma & Beverage Growth
- Why AptarGroup (ATR) International Revenue Trends Deserve Your Attention
- AptarGroup Inc (ATR) (Q2 2026) Earnings Call Highlights: Record Sales and Strategic Wins Amid ...
- AptarGroup (ATR) Tops Q2 Earnings and Revenue Estimates
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 46/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare AptarGroup, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is AptarGroup, Inc (ATR) overvalued or undervalued?
What is the fair value of ATR?
What is the quality score of ATR?
What is the revenue of AptarGroup, Inc (ATR)?
What is the net profit margin of ATR?
Does AptarGroup, Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track AptarGroup, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.